ReviewCancer imaging : the official publication of the International Cancer Imaging Society2026
O-RADS for assessment of adnexal lesions: current status, challenges and future directions.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ovarian-Adnexal Reporting and Data System (O-RADS), developed by the American College of Radiology (ACR), provides a standardized, evidence-based framework for risk stratification and management of ovarian and adnexal lesions. The O-RADS system is comprised of two complementary imaging arms: ultrasound (US) and magnetic resonance imaging (MRI). O-RADS US serves as the primary imaging modality for adnexal lesion assessment, given its wide availability in outpatient and inpatient settings, relatively low cost, lack of ionizing radiation and the ability for real-time dynamic assessment. Using defined lexicon terms, lesions are stratified into five risk categories corresponding to an estimated malignancy risk with associated management recommendations. Validation studies have demonstrated high sensitivities for malignancy detection, good specificities, and strong interobserver agreement. The 2022 update refined selected descriptors to improve specificity while otherwise maintaining diagnostic performance and reproducibility, reinforcing the system's clinical utility. O-RADS MRI functions as a secondary, problem-solving tool for lesions that are technically limited or when MRI evaluation may add value. Validation studies have consistently shown excellent performance of O-RADS MRI with studies showing high specificities approaching 90-95% related to better characterization of solid tissue based on signal and dynamic enhancement characteristics. Together, O-RADS US and MRI establish a comprehensive, standardized approach that improves diagnostic confidence and optimizes patient management. Ongoing efforts focus on improving congruence between these two arms by addressing discrepancies, understanding and lowering barriers for adoption, and providing management recommendations for O-RADS MRI. Emerging evidence and evolving technologies, such as contrast-enhanced ultrasound (CEUS), quantitative imaging biomarkers and artificial intelligence (AI), may further advance the system. This review summarizes the background and validation of O-RADS US and O-RADS MRI, discusses their complementary roles, current challenges and barriers to adoption, and outlines future priorities and research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.